covid vaccines

To get you to go to hell with them

''. . . . and because he (Black america) doesn't know what he wants he tries to integrate with a Blue-eyed

wolf (caucasian people). don't you know anytime you see some sheep trying to integrate with wolves, those

sheep are sick. those sheep are out of their mind. and a sheep got more chance with a wolf, than you got

integrated with a white man (devil)'- malcolm x, from the teachings of the most honourable elijah muhammad

covid upates to help you forget:

BDO Survey: Blacks Reveal Why They Would Take the Vaccine

FDA Approves first COVID-19 Treatment Find Out When You Would Get the Vaccine

What It Really Feels Like to Get a COVID Vaccine

This is the Card You’d Get If You Take the Vaccine

Coronavirus Vaccine Coming Soon! Can You Get One?

New Covid Vaccine Show 90% Effectiveness in early Results

If There Were A Vaccine To Protect Against COVID-19, Would You Get It?

Remdesivir for COVID-19: A glimmer of Hope?

Why I'm taking the COVID vaccine

this article first appeared on Blackdoctor.org

3,000 Blacks Volunteered for Moderna’s COVID-19 Vaccine Trials

Drug makers are racing to create a solution to the pandemic pains and help those who have been disproportionately affected by coronavirus disease 2019 – even offering vaccine tests that included approximately 3,000 blacks to close the gap in health equity.Although the participation of blacks compared to other ethnic groups was low in Moderna’s phase three clinical trials this fall, the overall results proved to be a success. Last month, biotech giant Moderna announced that its clinical trials for the novel coronavirus was 94.5% effective. “These are obviously very exciting results,” said Dr. Anthony Fauci, the country’s top infectious disease specialist. “It’s just as good as it gets — 94.5% is truly outstanding.” Moderna, one of the pioneers in mRNA technology, is a Massachusetts-based company that is on the road to major breakthroughs in vaccine development against coronavirus. In fact, it was the second company to report positive results after pharmaceutical powerhouse Pfizer revealed its vaccine was over 90% effective in treating the virus. However, Moderna’s vaccine trials experienced a delay in October after the company’s private contractors had limited success in enlisting enough Black volunteers. The clinical trial, conducted in collaboration with Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases, included more than 30,000 volunteers in the US aged 18 and over. There were approximately 7,000 volunteers over age 65. About 5,000 volunteers were under the age of 65 with high-risk diabetes, cardiac disease, and obesity. There were twice as many Hispanic volunteers than Blacks: 6,000 vs. 3000. In a Press Release dated November 16th, 2020, Moderna said: “Preliminary analysis suggests a broadly consistent safety and efficacy profile across all evaluated subgroups.” Several Blacks who participated in Moderna’s trial had cases of the disease before taking the vaccine. Many reports have found that Blacks were more likely to be victims of preexisting conditions that predispose them to the Coronavirus disease and were less likely to have access to health insurance and remote work that would limit exposure. In addition, Blacks are three times more likely than whites to be infected by coronavirus, and Blacks are twice as likely to die from the virus according to various reports. "The coronavirus disease epidemic that upended every aspect of American life has exposed the naked face of institutional and interpersonal racism," says Marc H. Morial, President & CEO of the National Urban League. There has been a long-standing mistrust of the healthcare system among blacks ever since the Tuskegee Syphilis Experiment began in 1932. Black men, many who were sharecroppers who had never visited a doctor, enrolled in the Tuskegee project in exchange for free medical care. Unfortunately, hundreds of

sharecroppers who had never visited a doctor, enrolled in the Tuskegee project in exchange for free medical care. Unfortunately, hundreds of black men died from the disease because adequate treatment was withheld from them, causing unnecessary pain and suffering. Moderna’s trial, known as the COVE study, involved 15,000 participants who were given a placebo, a shot of saline that has no effect. The other half of study participants were given the COVID-19 vaccine. When the results were delivered for the participants who were given a placebo, reports showed that 90 of them developed COVID-19. The impacted participants included 12 Hispanics, four Blacks, and three Asians. Moderna's clinical trials may potentially move everyone a step closer to the answers that are needed – aiming to provide immediate support to those most vulnerable to COVID-19 to “This is a pivotal moment in the development of our COVID-19 vaccine candidate,” said Stéphane Bancel, CEO of Moderna. “We have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease. This milestone is only possible because of the hard work and sacrifices of so many. I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus. They are an inspiration to us all.” Moderna received $1 billion from the U.S. government’s Operation Warp Speed to help develop its mRNA vaccine and $1.5 billion for future distribution. The company aims to provide the U.S. government with 20 million doses by the end of the month although there is still uncertainty about the length of time that the protection from the vaccine would last. On Monday, Moderna applied to the Food and Drug Administration to authorize the vaccine for emergency use, providing the possibility for the first shots to be given as early as December 21st if authorization is granted. More than 64 million corona virus cases have been confirmed globally with the U.S. accounting for over 20% (13.7 million) of the total cases, according to data from the Johns Hopkins Corona virus Resource Center. Unfortunately, death rates have been climbing as exposure spreads — more than 270,000 U.S. and over 1.4 million global deaths have been reported.

hargeisa, somaliland population 1,250,000

brazzaville, republic of congo population 2,200,000

havana, cuba population 3,000,000 port au prince, haiti population 800,000 kumasi, ghana population 1,600,000 lome, togo population 900,000

dar es salaam, tanzania population 3,500,000 matola, mozambique population 725,000 panama city, panama population 600,000

riyadh, saudi arabia population 9,000,000 gaborone, botswana population 300,000

mombasa, kenya population 900,000 kuala lumpur, malaysia population 2,000,000

kingston, jamaica population 1,500,000

luanda, angola population 4,000,000

phnom penh, cambodia population 2,500,000

addis ababa, ethiopia population 3,500,000

sanaa, yemen population 3,000,000

kinshasa, dr congo population 9,000,000

harare, zimbabwe population 2,500,000

shanghai, china population 22,000,000 cairo, egypt population 12,000,000

maracaibo, venezuela population 2,000,000 windhoek, namibia population 300,000

mexico city, mexico population 10,000,000 brikama, gambia population 85,000

nouakchott, mauritania population 750,000 kandahar, afghanistan population 600,000
khartoum, sudan population 3,000,000 kigali, rwanda population 850,000

ouagadougou, burkina faso population 2,000,000 quezon city, philippines population 4,000,000 bangui, central african republic population 620,000 n'djamena, chad population 850,000

anju, north korea population 400,000 libreville, gabon population 700,000

mumbai, india population 18,000,000 cape town, south africa population 4,500,000
georgetown, guyana population 300,000 sousse, tunisia population 250,000 lagos, nigeria population 10,000,000 ho chi minh, vietnam population 9,500,000 bata, equatorial guinea population 300,000 cotonou, benin population 900,000

dakar, senegal population 3,200,000 bafata, guinea bissau population 35,000 mako, mali population 2,500,000 faisalabad, pakistan population 3,500,000

niamey, niger population 900,000 mogadishu, somalia population 3,000,000 bujumbura, burundi population 450,000 ndola, zambia population 450,000